"Adcytherix Secures €105 Million Series A Funding to Advance Next-Generation Antibody-Drug Conjugates"

"McDermott Will & Schulte advised Adcytherix, a biopharmaceutical company focused on developing proprietary antibody-drug conjugates (ADCs), in a €105 million Series A funding round. The funding, led by Bpifrance and co-led by Kurma Partners, Andera Partners, and Angelini Ventures, will accelerate the development of Adcytherix's next-generation ADC portfolio. The company aims to advance its lead candidate, ADCX-020, to clinical stages by submitting investigational new drug applications in the U.S. and clinical trial applications in Europe, the UK, and Canada by the end of 2025."

McDermott Will & Schulte advised Adcytherix, a biopharmaceutical company specializing in the design and development of proprietary antibody-drug conjugates (ADCs), in a €105 million Series A fundraising round. This funding round was led by Bpifrance through its Large Venture and InnoBio funds, co-led by Kurma Partners, Andera Partners, and Angelini Ventures, alongside a consortium of leading international investors, including Surveyor Capital (a Citadel company) and aMoon. Founders and historical investors also participated in this round. The Series A positions Adcytherix as one of the most promising players in the ADC field and will enable the company to advance its lead candidate, ADCX-020, to the clinical stage, with the submission of the first investigational new drug (IND) applications in the United States and clinical trial applications (CTA) in the EU, UK, and Canada expected by the end of 2025. Additionally, Adcytherix will expand its portfolio of proprietary ADCs using innovative payloads. The McDermott team on this transaction included Emmanuelle Trombe, Partner; Lucie Martin, Counsel; and Pauline Orliange, Associate, all in the Life Sciences practice. Côme de Saint Vincent, Partner, provided expertise in tax law.

"Adcytherix Secures €105 Million Series A Funding to Advance Next-Generation Antibody-Drug Conjugates"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads